International orthopedic devices company Wright Medical Group (WMGI ? Analyst Report) recently reported that its Board of Directors chose Mr. Robert J. Palmisano as President and CEO, starting from September 17, 2011. Mr. David D. Stevens, who was interim President and CEO, will remain Chairman of the Board.
Mr. Palmisano has notable expertise managing important listed medtech companies. Until recently, he was President and CEO of ev3. During his 2-year stint there, the market capitalization of ev3 jumped more than three fold, from about $800 million in April 2008 to $2,600 million in July 2010.
Mr. Palmisano was President and CEO of IntraLase Corp. prior to joining ev3. Still earlier, he was President and CEO of MacroChem Corporation. He also served as President and CEO of Summit Technology Inc. until it was taken over by Alcon Inc (ACL ? Analyst Report). Mr. Palmisano occupied several executive posts at Bausch Lomb Incorporated between 1984 and 1996. He is at present a venture partner of SV Life Sciences and is on the Board of Directors of Bausch Lomb.
Wright Medical stated that as an incentive for Mr. Palmisano?s leadership at the company, it had authorized the grant of a stock option to him, which was made on September 17, 2011, to buy up to 610,000 shares at an exercise price of $16.03, subject to various terms and conditions.
As Mr. Palmisano assumes the mantle, Wright Medical is for the time being withdrawing its earlier released outlook for revenues and earnings. The company will release updated data on revenues and earnings outlook at its forthcoming third quarter earnings conference call.
Wright Medical Group is a global orthopedic devices company specializing in the development and marketing of reconstructive joint devices and bio-orthopedic materials. It is a leader in the U.S. market for foot and ankle surgical products. The company retains its strength in the niche extremities segment.
We feel future revenue growth will be supported by new product (including internally developed and those from acquisitions) launches. During second-quarter 2011, Wright Medical announced the commercial launch of new products for the foot and ankle market including the INBONE II total ankle replacement system. Moreover, new deals in extremities, Wright Medical?s fastest growing segment, are expected to bolster growth in this business. Within extremities, foot and ankle products are expected to be a major growth driver.
However, our views are moderated by lingering compliance issues and intense competition from larger orthopedic players. Wright Medical competes with much larger players such as Zimmer Holdings (ZMH ? Analyst Report), Stryker (SYK ? Analyst Report), Johnson Johnson?s (JNJ ? Analyst Report) De Puy and Smith Nephew (SNN ? Snapshot Report). Moreover, the company remains exposed to pricing/procedure volume headwinds. We currently have a long-term Neutral recommendation on the stock, backed by a short-term Zacks #3 Rank (Hold).
Read the full analyst report on SYK
Read the full analyst report on ZMH
Read the full analyst report on SNN
Read the full analyst report on ACL
Read the full analyst report on WMGI
Read the full analyst report on JNJ
Share
RSS
Rate Pos
Rate Neg
Comment
Please login or register to post a comment
Loading Stories?
Related Content
Read/Post Comments (0) | Recommended this article (2)
Posting Comment?There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters ? Used: 0)
Please provide your comments here?
Display Name: Email Address:
Loading Comments?Be the first to comment on this article!
Related Tickers
Symbol
Price
Net
% Change
Zacks
Rank
Zacks
Rec
SYK48.49-$0.01-0.02 %PREMIUMPREMIUMZMH57.29$0.791.40 %PREMIUMPREMIUMSNN46.69-$0.27-0.57 %PREMIUMPREMIUMACL0.00$0.000.00 %PREMIUMPREMIUMWMGI18.01$0.613.51 %PREMIUMPREMIUMJNJ64.22$0.080.12 %PREMIUMPREMIUM
More Zacks Links
Free MembershipZacks RankMy PortfolioEquity ResearchStock ScreenerMutual FundsZacks VideoOptionsProfit TracksRSS Feed?Profit from the Pros
DJIA
11408.66
?7.65
0.07%
NASD
2590.24
?-22.59
-0.86%
SP 500
1202.09
?-2.00
-0.17%
<!?
Sponsored Links
google_ad_client = ?pub-2333136737514314?;
/* 300?250, created 3/26/09 */
google_ad_slot = ?1731613220?;
google_ad_width = 300;
google_ad_height = 250;
?>
Copyright 2011 Zacks Investment Research
Zacks Investment Research is one of the most highly regarded firms in the investment industry. The guiding principle behind our work is that there must be a good reason for brokerage firms to spend billions of dollars a year on stock research. Obviously, these investment experts know something special that may be indicative of the future direction of stock prices. From day one, we were determined to unlock that secret knowledge and make it available to our clients to help them improve their investment results.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
<!? ?>
Article source: http://www.zacks.com/stock/news/61106/Wright+Medical+Gets+a+New+CEO
Related posts:
- Wright Medical taps veteran exec as CEO
- Wright Medical Group names Robert Palmisano CEO
- Wright Medical names new CEO and president
- Wright Medical Names New CEO
- Wright Medical Names New CEO
Source: http://medicaltips.biz/2011/09/21/wright-medical-gets-a-new-ceo/
patch adams preamble preamble constitution constitution james carville james carville
No comments:
Post a Comment